BI-RADS in Breast Mass Assessment
BI-RADS (Breast Imaging Reporting and Data System) is the standardized classification system developed by the American College of Radiology for reporting breast imaging findings, not "BIRDS." This system categorizes breast lesions from 0-6 based on malignancy risk and provides specific management recommendations for each category 1, 2.
The Seven BI-RADS Categories
Category 0: Incomplete Assessment
- Additional imaging evaluation is needed before final assessment can be made 1, 2
- Almost exclusively used in screening situations requiring spot compression, magnification views, or ultrasound 2
Category 1: Negative
Category 2: Benign Findings
- Definitively benign findings present (calcifying fibroadenoma, oil cyst, lipoma, intramammary lymph nodes, vascular calcification) 1
- Management: Resume routine annual screening mammography 2
- Zero frequency of malignancy in properly classified BI-RADS 2 lesions, making breast biopsies unnecessary 3
Category 3: Probably Benign
- Malignancy risk less than 2% 1, 2
- Management: Initial follow-up at 6 months with diagnostic unilateral mammography, then every 6-12 months for 1-2 years 4, 2
- Immediate biopsy is reasonable in specific scenarios: high-risk patients, patients awaiting organ transplant, patients with known synchronous cancers, patients attempting pregnancy, or situations of extreme patient anxiety 5, 2
Category 4: Suspicious Abnormality
- Wide range of malignancy probability, greater than Category 3 but less than Category 5 1
- Management: Biopsy recommended 4, 2
- For BI-RADS 4C specifically: malignancy risk between 50-95%, requiring core needle biopsy for tissue diagnosis 6
Category 5: Highly Suggestive of Malignancy
- Malignancy probability ≥95% 1, 2
- Includes spiculated masses or malignant-appearing pleomorphic calcifications 1
- Management: Tissue diagnosis via core needle biopsy is mandatory 2
Category 6: Known Biopsy-Proven Malignancy
- Reserved for lesions with biopsy-confirmed malignancy prior to definitive treatment 1, 2
- Management follows breast cancer treatment guidelines 2
Critical Clinical Applications
Age-Specific Imaging Approach
- Women <30 years: Ultrasound is the initial imaging modality of choice, with diagnostic mammography added only if ultrasound shows suspicious findings or patient has BRCA/genetic mutations 2
- Women 30-39 years: Either ultrasound or diagnostic mammography/DBT can serve as initial imaging, with ultrasound sensitivity exceeding mammography in this age group 2
- Women ≥40 years: Diagnostic mammography or DBT is the appropriate initial imaging, with ultrasound added after mammography if findings are suspicious or targeted correlation is needed 2
Ultrasound Features Predicting Benignity vs. Malignancy
Benign descriptors include:
Suspicious descriptors include:
- Irregular shape 8, 9
- Non-circumscribed margins 8, 9
- Non-parallel (antiparallel) orientation 8, 9
- Echogenic halo 8, 9
- Posterior acoustic shadowing 10, 8, 9
Important Concordance Principle
- BI-RADS categories represent cumulative findings when multiple imaging modalities are performed (e.g., mammography plus ultrasound) 1
- The overall assessment is based on the most worrisome finding when multiple abnormalities are identified 2
- Pathology-imaging concordance is essential: if pathology and imaging are discordant, repeat imaging and/or additional tissue sampling is mandatory 4, 2
Common Pitfalls to Avoid
- Do not delay biopsy for BI-RADS 4C lesions: approximately 50% of initially benign biopsies that are discordant with imaging prove malignant on repeat biopsy 6, 10
- Do not perform short-interval follow-up for suspicious findings: in the context of suspicious mammographic findings and palpable masses, direct biopsy should be performed rather than observation 5
- Recognize false-positive imaging: benign lesions (particularly fibrocystic changes) can mimic malignancy on imaging, with oval shape being more common in benign pathology and posterior shadowing being less common 10